novo nordisk cagrilintide Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts Novo Nordisk shares plunge after
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters Novo Nordisk's CagriSema Next Gen Weight Loss Treatment Healthcare Digital Novo Nordisk Offers New Contender in Weight Management Weight loss: New drug CagriSema leads to 14% weight loss in trial
Pay in 4 interest-free payments of $6.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


